These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 24263061)

  • 1. Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance.
    Gerlach MM; Merz F; Wichmann G; Kubick C; Wittekind C; Lordick F; Dietz A; Bechmann I
    Br J Cancer; 2014 Jan; 110(2):479-88. PubMed ID: 24263061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
    Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
    Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells.
    Johansson AC; Ansell A; Jerhammar F; Lindh MB; Grénman R; Munck-Wikland E; Östman A; Roberg K
    Mol Cancer Res; 2012 Sep; 10(9):1158-68. PubMed ID: 22809838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
    De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
    Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term culture of tumour slices reveals the heterogeneous sensitivity of human head and neck squamous cell carcinoma to targeted therapies.
    Donnadieu J; Lachaier E; Peria M; Saidak Z; Dakpe S; Ikoli JF; Chauffert B; Page C; Galmiche A
    BMC Cancer; 2016 Apr; 16():273. PubMed ID: 27085492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Notch inhibitor, FLI-06, increases the chemosensitivity of head and neck Squamous cell carcinoma cells to taxanes-based treatment.
    Czerwonka A; Kałafut J; Wang S; Anameric A; Przybyszewska-Podstawka A; Toriseva M; Nees M
    Biomed Pharmacother; 2024 Aug; 177():116822. PubMed ID: 38906029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: a pilot study.
    Yoo GH; Lin HS; Iskander AJ; Piechocki MP; Oliver J; Kewson D; Lonardo F; Tainsky MA; Kim HR; Kim H; Ensley JF
    Laryngoscope; 2005 Nov; 115(11):1938-46. PubMed ID: 16319602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.
    Klinghammer K; Otto R; Raguse JD; Albers AE; Tinhofer I; Fichtner I; Leser U; Keilholz U; Hoffmann J
    Int J Cancer; 2017 Sep; 141(6):1215-1221. PubMed ID: 28560858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
    Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G
    Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
    Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
    Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
    Pogorzelski M; Ting S; Gauler TC; Breitenbuecher F; Vossebein I; Hoffarth S; Markowetz J; Lang S; Bergmann C; Brandau S; Jawad JA; Schmid KW; Schuler M; Kasper S
    Cell Death Dis; 2014 Feb; 5(2):e1091. PubMed ID: 24577089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
    Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
    Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
    Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
    Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.
    Jiang N; Wang D; Hu Z; Shin HJ; Qian G; Rahman MA; Zhang H; Amin AR; Nannapaneni S; Wang X; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Ma J; Chen ZG; Saba NF
    Mol Cancer Ther; 2014 Jul; 13(7):1826-36. PubMed ID: 24748655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
    Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
    J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
    Bu LL; Zhao ZL; Liu JF; Ma SR; Huang CF; Liu B; Zhang WF; Sun ZJ
    Oncotarget; 2015 Dec; 6(39):41944-58. PubMed ID: 26556875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of cisplatin sensitivity and the 18F fluoro-2-deoxy 2 glucose uptake with proliferation parameters and gene expression in squamous cell carcinoma cell lines of the head and neck.
    Henriksson E; Kjellén E; Baldetorp B; Bendahl PO; Borg A; Brun E; Mertens F; Ohlsson T; Rennstam K; Wennerberg J; Wahlberg P
    J Exp Clin Cancer Res; 2009 Feb; 28(1):17. PubMed ID: 19216775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinatorial Effects of Curcumin with an Anti-Neoplastic Agent on Head and Neck Squamous Cell Carcinoma Through the Regulation of EGFR-ERK1/2 and Apoptotic Signaling Pathways.
    Sivanantham B; Sethuraman S; Krishnan UM
    ACS Comb Sci; 2016 Jan; 18(1):22-35. PubMed ID: 26505786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
    Koch AT; Love-Homan L; Espinosa-Cotton M; Stanam A; Simons AL
    Cancer Res; 2015 Apr; 75(8):1657-67. PubMed ID: 25712126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
    Aderhold C; Umbreit C; Faber A; Sauter A; Sommer JU; Birk R; Erben P; Hofheinz RD; Stern-Straeter J; Hörmann K; Schultz JD
    Anticancer Res; 2013 May; 33(5):1951-61. PubMed ID: 23645743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.